Genflow Biosciences Stock Price, News & Analysis

Genflow Biosciences (GENFF) has entered into a strategic partnership with Heureka Labs, signing a Master Services Agreement on April 11, 2025. The collaboration provides Genflow access to Heureka's proprietary AI platform, specialized in analyzing genomic data and gene expression profiles.

The partnership will support Genflow's lead candidate GF-1002, a SIRT6-based gene therapy in preclinical evaluation, and may extend to other programs including those targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). Under the agreement, Genflow retains all IP rights.

Heureka Labs, a Duke University technology spin-off, offers an AI platform currently used by leading pharmaceutical companies to accelerate drug discovery through hypothesis generation and pattern recognition in biological data.

Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only public longevity company, has announced a new ophthalmology development program focusing on novel gene therapy using their proprietary Centenarian SIRT6 (cSIRT6) technology.

The program will utilize a specially designed non-viral vector for precise delivery of SIRT6 to the eye, targeting ocular conditions including corneal pathologies and glaucoma. The company has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector.

According to CEO Dr. Eric Leire, the eye's closed and accessible compartment makes it an ideal target for gene therapy, with SIRT6 showing promising potential in treating corneal endothelial disorders and glaucoma.

Genflow Biosciences PLC (GENFF) has reported a change in company holdings through an acquisition or disposal of voting rights. The notification was submitted by Mr. Eric Leire on March 27, 2025, regarding a threshold crossing in shareholding that occurred on the same date. The disclosure was made in compliance with UK regulatory requirements and filed through the London Stock Exchange's news service (RNS).

The regulatory filing, completed in London, indicates a change in voting rights position, though specific details about the size and direction of the holding change were not disclosed in the announcement.

Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only listed longevity company, has announced significant director dealings. The company's CEO, Dr. Eric Leire, has made a substantial insider purchase of 2,100,000 ordinary shares at 1.15 pence per share on the open market on March 27, 2025. The transaction was executed in London and disclosed in accordance with UK Market Abuse Regulation requirements.

Genflow Biosciences (LSE:GENF/OTCQB:GENFF) has secured an institutional investment of £434,083 through a binding offer for 41,341,324 Ordinary Shares at 1.05p per share. The shares will be issued after April 9, 2025, with trading admission expected around April 10, 2025.

Company Director Eric Leire intends to invest an additional £50,000 under the same terms. Following the share issuance, the company's enlarged issued share capital will comprise 391,047,942 ordinary shares.

The funding, combined with previous government grants, will support Genflow's 2025 programs, particularly a newly launched proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs. The trial will involve 28 dogs aged 10+ years, conducted with CRO Syngene, focusing on biological age estimation, muscle strength, muscle mass, mitochondrial function, coat quality, and overall health indicators over a 12-month period.

Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announced significant progress in its patent application for SIRT6 variants, aimed at preventing and treating age-related diseases. The European patent application (EP 22 808 414.1), filed on May 13, 2022, has successfully cleared the Supplementary European Search Report without additional queries from the European Patent Office.

The patent application, originally filed by the University of Rochester, The Trustees of Columbia University, and the Albert Einstein College of Medicine, focuses on SIRT6 gene/protein variants, which play important roles in DNA repair, metabolism, and longevity. The application has now advanced to the national phase of the patent process, with Genflow preparing to proceed by July 7, 2025.

Genflow Biosciences PLC (GENFF) has reported a significant change in shareholding. Jonathan Mark Swann from Rickmansworth, UK, has increased his voting rights in the company from 5.03% to 6.01%, representing 21,025,000 voting rights. The threshold was crossed on January 10, 2025, and the company was notified on January 13, 2025.

The notification indicates this change resulted from an acquisition of voting rights, with all shares being held directly. No financial instruments or similar economic instruments were reported as part of this holding. The shareholder is not controlled by any natural person or legal entity and does not control any other undertaking holding interests in Genflow Biosciences.

Genflow Biosciences PLC has reported a significant change in shareholding, with Premier Miton Group plc crossing a notification threshold on January 9, 2025. The investment firm now holds 15,147,262 voting rights, representing 4.33142% of the company's total voting rights, down from their previous position of 9.15053%.

The change was due to an acquisition or disposal of financial instruments, as reported through a standard TR-1 form. The notification was formally submitted on January 10, 2025, with Premier Fund Managers , a controlled undertaking of Premier Miton Group plc, being the entity holding the voting rights.

Genflow Biosciences has reported key developments for 2024 in their aging-focused therapeutic programs. The company's MASH program (GF-1002) is advancing to pre-IND phase, partnering with Exothera SA for GMP manufacturing of clinical lots. For Werner Syndrome (GF-1003), they've developed proprietary liver organoids from human patient cells. The Dog Aging program (GF-1004) is initiating a six-month life extension clinical trial in collaboration with Syngene, expected to complete analysis by end of 2025.

Their Sarcopenia program (GF-1005) is progressing with myoblast progenitor studies in partnership with Université libre de Bruxelles, focusing on mitochondrial dysfunction. The company received support from the Belgian Government and has strengthened its research collaborations throughout the year.